Rhythm Pharmaceuticals (RYTM) director granted RSUs, options and new shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

RHYTHM PHARMACEUTICALS director Jennifer L. Good reported equity awards and an option-related share issuance. On June 24, 2026, she received 2,324 restricted stock units and options for 3,691 shares of common stock at an exercise price of $107.55 per share. The new RSUs and options fully vest on the earlier of June 24, 2027 or the day immediately before the company’s 2027 annual stockholder meeting, subject to her continued service. On June 23, 2026, 4,712 previously granted RSUs were converted into 4,712 shares of common stock, increasing her direct common stock holdings to 11,712 shares.

Insider Trade Summary

4,712 shares exercised/converted

Mixed 4 txns

Insider GOOD JENNIFER L

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	3,691	$0.00	--
Grant/Award	Restricted Stock Units	2,324	$0.00	--
Exercise	Restricted Stock Units	4,712	$0.00	--
Exercise	Common Stock	4,712	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 3,691 shares (Direct, null); Restricted Stock Units — 2,324 shares (Direct, null); Common Stock — 11,712 shares (Direct, null)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units are fully vested. The restricted stock units have no expiration date. The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

Key Figures

New RSU grant: 2,324 units New stock options: 3,691 options at $107.55 RSUs converted: 4,712 shares +2 more

5 metrics

New RSU grant 2,324 units Restricted stock units granted on June 24, 2026

New stock options 3,691 options at $107.55 Option grant on June 24, 2026, exercise price per share

RSUs converted 4,712 shares Common shares issued from RSU conversion on June 23, 2026

Post-transaction holdings 11,712 shares Common stock directly held after June 23, 2026 transaction

Option expiration June 23, 2036 Expiration date of 3,691-share stock option grant

Key Terms

Restricted Stock Units, Stock Option, exercise or conversion of derivative security, vesting

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option financial

"The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting..."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

vesting financial

"The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 06:02 PM Accepted by SEC EDGAR 06/25/2026 - 06:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOOD JENNIFER L

(Last)

(First)

(Middle)

C/O RHYTHM PHARMACEUTICALS, INC.

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON

MASSACHUSETTS

02116

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/23/2026		M		4,712	A	⁽¹⁾	11,712	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	06/23/2026		M			4,712	⁽²⁾	⁽²⁾	Common Stock	4,712	$0	0	D
Stock Option (right to buy)	$107.55	06/24/2026		A		3,691		⁽³⁾	06/23/2036	Common Stock	3,691	$0	3,691	D
Restricted Stock Units	⁽¹⁾	06/24/2026		A		2,324		⁽⁴⁾	⁽⁴⁾	Common Stock	2,324	$0	2,324	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

2. The restricted stock units are fully vested. The restricted stock units have no expiration date.

3. The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.

4. The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

	/s/ Stephen Vander Stoep, attorney-in-fact for Jennifer L. Good	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Rhythm Pharmaceuticals (RYTM) report for Jennifer L. Good?

Jennifer L. Good received equity awards and exercised RSUs. She was granted 2,324 restricted stock units and options for 3,691 shares, and 4,712 fully vested RSUs converted into 4,712 common shares, bringing her direct holdings to 11,712 shares.

How many Rhythm Pharmaceuticals (RYTM) shares does Jennifer L. Good hold after these transactions?

After the reported transactions, Jennifer L. Good directly holds 11,712 shares of Rhythm Pharmaceuticals common stock. This includes 4,712 shares issued upon conversion of previously granted restricted stock units, as disclosed in the Form 4 insider filing.

What stock option grant did Jennifer L. Good receive from Rhythm Pharmaceuticals (RYTM)?

She received a stock option covering 3,691 shares of Rhythm Pharmaceuticals common stock at an exercise price of $107.55 per share. The options fully vest by June 24, 2027 or just before the 2027 annual stockholder meeting, subject to continued service.

What restricted stock unit (RSU) awards did Rhythm Pharmaceuticals (RYTM) grant to Jennifer L. Good?

On June 24, 2026, she was granted 2,324 restricted stock units, each representing one share of common stock. These RSUs fully vest by June 24, 2027 or the day before the 2027 annual meeting, subject to her continued service as disclosed.

Were any of Jennifer L. Good’s Rhythm Pharmaceuticals (RYTM) awards already fully vested?

Yes. The filing states that a block of restricted stock units was fully vested and had no expiration date. On June 23, 2026, 4,712 of those vested RSUs converted into 4,712 shares of Rhythm Pharmaceuticals common stock.